STAT Plus: Pharmalittle: Connecticut lawmakers look to cap insulin prices; Glaxo halts Excedrin production
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch.
Senate Democratic leaders in Connecticut unveiled their health care reform agenda for the legislative session that begins next month, saying they aim to cap the price of insulin and limit the cost of other prescription drugs, The CT Mirror reports. Few details were revealed about the insulin bill, but it is modeled after an effort in Colorado that caps copayments on insulin at $100 a month for insured patients, regardless of the supply they require. Insurance companies must absorb the balance. The Colorado law also directs the state’s attorney general to launch an investigation into how prescription insulin prices are set throughout the state and make recommendations to the legislature.
Continue to STAT Plus to read the full story…
